Mesa Biotech

History

2021: Thermo Fisher Scientific purchased Mesa Biotech for $450 million

At the end of January, 2021 the Thermo Fisher Scientific company announced acquisition of private producer of molecular diagnostics Mesa Biotech for $450 million with a possibility of receiving additional $100 million upon completion of certain stages of sales. It is expected that the deal will be closed in the first quarter 2021.

This acquisition will allow Thermo Fisher to add to the portfolio the platform for express testing of Accula on the basis of PTsR which allows to hold testing for SARS-CoV-2, flu A and B, RSV and a streptococcus of A at the patient's bed. The Accula SARS-CoV-2 test of Mesa Biotech company which yields results in 30 minutes was one of the first rapid tests for COVID-19 which got the emergency permission of regulatory bodies. The technology was developed in National laboratory of Los Alamos with assistance of grants of National Institute of an allergy and infectious diseases and the Western regional centers of the best practices in programs of biological protection and studying of new infectious diseases.

Thermo Fisher Scientific purchased Mesa Biotech

The chief operating officer of Thermo Fisher Mark Stevenson noted that new technologies and 500 employees of Mesa company will help Thermo Fisher to meet stable demand for testing of COVID-19 and also to scale production and to develop rapid tests for other infectious diseases. The revenues of Thermo Fisher connected with COVID-19 sharply grew by 34% that is caused by high demand on tools for testing.

Mesa purchase - the second large acquisition of Thermo Fisher less than in a week. Earlier the company announced that it redeemed from Novasep business on production of virus vectors approximately for $880 million to meet the growing global demand for cellular/gene vaccines and medicines.^[1]

Notes